TP53 and hepatocellular carcinoma: In part to increase the number of potential therapeutic targets, investigators from The Cancer Genome Atlas (TCGA) Research Network identified genomic alterations in 196 tumors that influence development of HCC, including mutations in the TERT gene promotor, mutations in the TP53 and CTNNB1 (β-catenin) genes, and elevated expression of several immune checkpoint genes 14.